- HMN-176
-
- $51.00 / 2mg
-
2025-05-01
- CAS:173529-10-7
- Min. Order:
- Purity: 98.99%
- Supply Ability: 10g
- HMN 176
-
- $1.00 / 1g
-
2019-12-23
- CAS:173529-10-7
- Min. Order: 1g
- Purity: 99.99%
- Supply Ability: 200kg
|
| | HMN 176 Basic information |
| Product Name: | HMN 176 | | Synonyms: | HMN 176;HMN-176;(NE)-N-[(6E)-6-[2-(1-hydroxypyridin-4-ylidene)ethylidene]cyclohexa-2,4-dien-1-ylidene]-4-methoxybenzenesulfonamide;CS-2239;HMN 176; HMN176;Benzenesulfonamide, 4-methoxy-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-;Polo-like Kinase (PLK),HMN-176,HMN176,HMN 176,Inhibitor,inhibit;(E)-4-(2-((4-Methoxyphenyl)sulfonamido)styryl)pyridine 1-oxide | | CAS: | 173529-10-7 | | MF: | C20H18N2O4S | | MW: | 382.43 | | EINECS: | | | Product Categories: | API | | Mol File: | 173529-10-7.mol |  |
| | HMN 176 Chemical Properties |
| Boiling point | 632.9±65.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO : ≥ 30 mg/mL (78.45 mM) | | form | Solid | | pka | 8.07±0.10(Predicted) | | color | White to off-white |
| | HMN 176 Usage And Synthesis |
| Uses | HMN-176?is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.? | | in vivo | After p.o. of HMN-214 to male rats, the prodrug is not detected in the plasma, while plasma levels of HMN-176 peaks at 2 h and gradually decreases thereafter[3]. | | References | [1] DiMaio MA, et al. The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation. Mol Cancer Ther. 2009 Mar;8(3):592-601. DOI:10.1158/1535-7163.MCT-08-0876
[2] Medina-Gundrum L, et al. Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression. Invest New Drugs. 2005 Jan;23(1):3-9. DOI:10.1023/B:DRUG.0000047100.64540.f6
[3] Takagi M, et al. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs. 2003 Nov;21(4):387-99. DOI:10.1023/a:1026282716250
[4] Tanaka H, et al. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res. 2003 Oct 15;63(20):6942-7. PMID:14583495
[5] Garland LL, et al. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 1;12(17):5182-9. DOI:10.1158/1078-0432.CCR-06-0214 |
| | HMN 176 Preparation Products And Raw materials |
|